Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society’s 65th Annual Scientific Meeting

Oral Presentation: Sustained Efficacy of STS101 DHE Nasal Powder for the Acute Treatment of Migraine: Results from the Phase­3 Double-Blind, Randomized, Placebo-Controlled SUMMIT Study

DURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395), today announced that three abstracts describing efficacy and safety results from the STS101 Phase 3 efficacy trial were selected for presentation at the American Headache Society’s (AHS) 65^th Annual Scientific Meeting. The 2023 meeting will be held in a hybrid virtual and in-person format at the JW Marriott in Austin, Texas from Thursday, June 15 to Sunday, June 18, 2023. Full abstracts are now available on the AHS website and will be published in the journal Headache.

Oral Presentation Details:
Title:			Sustained Efficacy of STS101 DHE Nasal Powder for the Acute Treatment of Migraine: Results from the Phase­3 Double-Blind, Randomized, Placebo-Controlled SUMMIT Study
Presenter:			Alan Rapoport, MD, Professor of Neurology, David Geffen School of Medicine University of California Los Angeles (UCLA)
Date:			Saturday, June 17, 2023
Time:			7:50 AM - 8:00 AM CT (8:50 AM – 9:00 AM ET)
Location:			Lone Star Ballroom D-E
Poster Presentation Details:
Title:			Efficacy of STS101 DHE Nasal Powder for the Acute Treatment of Difficult to Treat Migraines: Results from the Phase 3 Double-Blind, Randomized, Placebo-Controlled SUMMIT Study
Presenter:			Jessica Ailani, MD
Date:			Friday, June 16, 2023
Time:			1:35 PM – 2:50 PM CT (2:35 PM – 3:50 PM ET)
Title:			Efficacy and Safety of STS101 DHE Nasal Powder for the Acute Treatment of Migraine: Results from the Phase 3 Double-Blind, Randomized, Placebo-Controlled SUMMIT Study
Presenter:			Richard B. Lipton, MD
Date:			Saturday, June 17, 2023
Time:			1:45 PM – 3:09 PM CT (2:45 PM – 4:09 PM ET)